Abstract:Background Intravitreal injection of ranibizumab (IVR) is one of the most effective therapies for neovascular age-related macular degeneration (nAMD).Understanding the influence of IVR on retinal pigment epithelium (RPE) and choroidal thickness is helpful for us to choose the operative times and timing based on pharmacologic effects and tissue response.However,limited studies are available about quantitative analysis of RPE atrophic area and subfoveal choroidal thickness after IVR for nAMD.Objective This study was to report the changes of RPE atrophic area and subfoveal choroidal thickness after IVR for nAMD.Methods A prospective series cases-observational study was designed.Forty-one eyes of 41 consecutive patients with nAMD were enrolled in Renmin Hospital of Wuhan University from January 2015 to June 2015,and written informed consent was obtained from each patient prior to entering the cohort.The affected eyes received intravitreal injection of 0.05 ml ranibizumab (10 mg/ml) and then followed up monthly for 12 months.The RPE atrophy area around macula and subfoveal choroidal thickness were measured by a newly developed RPE analysis software spectral-domain optical coherence tomography (OCT) and enhanced depth imaging of SD-OCT (EDI-OCT),respectively,and the RPE atrophy area and choroidal thickness changes were compared before IVR and 3,6 and 12 months after IVR.The correlation between RPE atrophy area and choroidal thickness before and after IVR was analyzed.Results All the patients finished the treating procedure and follow up.The visual acuity (logMAR) after IVR was considerably improved in comparison with before IVR (F=7.631,P＜0.001).The mean subfoveal choroidal thickness value was (264.55 ± 100.95) μm before IVR,and that of 3,6,12 months after IVR was (247.42±105.46),(246.81± 99.85) and (253.97±101.15)μm,respectively,showing a significant difference among different time points (F =2.030,P ＜ 0.05),and the mean subfoveal choroidal thickness values 3,6,12 months after IVR were evidently thinned in comparison with before IVR (all at P＜0.05).No significant difference was found in RPE atrophic area among different time points (F=0.116,P =0.951).Weak linear correlations were seen between RPE atrophy area and choroidal thickness (r =-0.185),the RPE atrophy area change values and choroidal thickness change values between IVR ＞ 6 times and ≤ 6 times (r =0.297,-0.327),but these results were not statistically significant (P =0.248,0.282,0.103).At the end of the follow up,weak linear correlations were seen in RPE atrophy area change values and choroidal thickness change values with IVR times (r,=-0.266,0.342),but these results were not statistically significant (P =0.148,0.060).Conclusions IVR for nAMD can lead to subfoveal choroid atrophy instead of RPE atrophy.IVR does not accelerate the atrophy progression of both RPE and choroid.

Long-term Efficacy of Intravitreal Ranibizumab Therapy for Idiopathic Choroidal Neovascularization

Idiopathic Choroidal Neovascularization: Intraocular Inflammatory Cytokines and the Effect of Intravitreal Ranibizumab Treatment

Intravitreal ranibizumab for treatment of idiopathic choroidal neovascularization: results of a 6-month retrospective trial

Evaluation of Efficacy and Recurrence for Anti-Vascular Endothelial Growth Factor Therapy in Idiopathic Choroidal Neovascularization

Intravitreal anti-vascular endothelial growth factor in the treatment of idiopathic choroidal neovascularization:a retrospective analysis

Using Optical Coherence Tomography Angiography (OCTA) to Observe Thecurative Effect of Intravitreal Injection of Ranibizumab for the Treatment of Idiopathic Choroidal Neovascularization (ICNV)

Clinical Efficacy of Intravitreal Ranibizumab in Idiopathic Choroid Neovascularization Type Ⅰand Type Ⅱ

Assessment of Three Successive Treatments of Ranibizumab on Neovascular Macular Degeneration by OCT Angiography.

Effect of Intravitreal Injection of Anti VEGF Drugs on BCVA and Mferg Before and after Treatment for MCNV and ICNV

Long-term Outcome of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy with Bevacizumab or Ranibizumab As Primary Treatment for Subfoveal Myopic Choroidal Neovascularization

Intravitreal Injection of Ranibizumab for the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

Influence of repetitive intravitreal ranibizumab for neovascular age-related macular degeneration on retinal pigment epithelium and choroidal thickness

Clinical Observation of Intravitreal Injection of Conbercept Treating Idiopathic Choroidal Neovascularization

Outcome of Intravitreal Bevacizumab for Idiopathic Choroidal Neovascularization in a Chinese Population

Comparison of clinical efficacy of intravitreal ranibizumab with and without grid laser photocogagulation for macular edema secondary to branch retinal vein occlusion

Two Different Initial Treatment Regimens Of Ranibizumab In Myopic Choroidal Neovascularization: 12-Month Results From A Randomized Controlled Study-Response

Visual Acuity and Retinal Thickness and Sensitivity after Intravitreal Ranibizumab Injection for Macular Edema in Branch Retinal Vein Occlusion

Intravitreal bevacizumab injection on idiopathic choroidal neovascularization

Changes in Clotting Time, Plasma Fibrinogen Levels, and Blood Viscosity after Administration of Ranibizumab for Treatment of Choroidal Neovascularization

Clinical Observation of Intravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Pathologic Myopia

Effects of Intravitreal Ranibizumab Injection to Treat Macular Edema due to Central Retinal Vein Occlusion on Choroidal Findings and Functional-Morphological Parameters